183 related articles for article (PubMed ID: 18927512)
1. The cytotoxic ribonuclease onconase targets RNA interference (siRNA).
Zhao H; Ardelt B; Ardelt W; Shogen K; Darzynkiewicz Z
Cell Cycle; 2008 Oct; 7(20):3258-61. PubMed ID: 18927512
[TBL] [Abstract][Full Text] [Related]
2. Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines.
Ita M; Halicka HD; Tanaka T; Kurose A; Ardelt B; Shogen K; Darzynkiewicz Z
Cancer Biol Ther; 2008 Jul; 7(7):1104-8. PubMed ID: 18443430
[TBL] [Abstract][Full Text] [Related]
3. Effect of Onconase on double-stranded RNA in vitro.
Saxena A; Saxena SK; Shogen K
Anticancer Res; 2009 Apr; 29(4):1067-71. PubMed ID: 19414347
[TBL] [Abstract][Full Text] [Related]
4. Cytostatic and cytotoxic properties of Amphinase: a novel cytotoxic ribonuclease from Rana pipiens oocytes.
Ardelt B; Ardelt W; Pozarowski P; Kunicki J; Shogen K; Darzynkiewicz Z
Cell Cycle; 2007 Dec; 6(24):3097-102. PubMed ID: 18073526
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic ribonucleases and RNA interference (RNAi).
Ardelt B; Ardelt W; Darzynkiewicz Z
Cell Cycle; 2003; 2(1):22-4. PubMed ID: 12695680
[TBL] [Abstract][Full Text] [Related]
6. Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3.
Sun M; Tang H; Gao Y; Dai X; Yuan Y; Zhang C; Sun D
Oncol Rep; 2016 Apr; 35(4):1987-94. PubMed ID: 26782924
[TBL] [Abstract][Full Text] [Related]
7. The interdependence between catalytic activity, conformational stability, and cytotoxicity of onconase.
Schulenburg C; Ardelt B; Ardelt W; Arnold U; Shogen K; Ulbrich-Hofmann R; Darzynkiewicz Z
Cancer Biol Ther; 2007 Aug; 6(8):1233-9. PubMed ID: 17637563
[TBL] [Abstract][Full Text] [Related]
8. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity.
Wu Y; Mikulski SM; Ardelt W; Rybak SM; Youle RJ
J Biol Chem; 1993 May; 268(14):10686-93. PubMed ID: 8486718
[TBL] [Abstract][Full Text] [Related]
9. Role of the Ribonuclease ONCONASE in miRNA Biogenesis and tRNA Processing: Focus on Cancer and Viral Infections.
Menegazzi M; Gotte G
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742999
[TBL] [Abstract][Full Text] [Related]
10. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
Ardelt W; Shogen K; Darzynkiewicz Z
Curr Pharm Biotechnol; 2008 Jun; 9(3):215-25. PubMed ID: 18673287
[TBL] [Abstract][Full Text] [Related]
11. Onconase dimerization through 3D domain swapping: structural investigations and increase in the apoptotic effect in cancer cells.
Fagagnini A; Pica A; Fasoli S; Montioli R; Donadelli M; Cordani M; Butturini E; Acquasaliente L; Picone D; Gotte G
Biochem J; 2017 Nov; 474(22):3767-3781. PubMed ID: 28963346
[TBL] [Abstract][Full Text] [Related]
12. Onconase, an anti-tumor ribonuclease suppresses intracellular oxidative stress.
Ardelt B; Juan G; Burfeind P; Salomon T; Wu JM; Hsieh TC; Li X; Sperry R; Pozarowski P; Shogen K; Ardelt W; Darzynkiewicz Z
Int J Oncol; 2007 Sep; 31(3):663-9. PubMed ID: 17671695
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice.
Lee I; Kalota A; Gewirtz AM; Shogen K
Anticancer Res; 2007; 27(1A):299-307. PubMed ID: 17352247
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase).
Halicka DH; Pozarowski P; Ita M; Ardelt WJ; Mikulski SM; Shogen K; Darzynkiewicz Z
Int J Oncol; 2002 Dec; 21(6):1245-50. PubMed ID: 12429974
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleases as potential modalities in anticancer therapy.
Ardelt W; Ardelt B; Darzynkiewicz Z
Eur J Pharmacol; 2009 Dec; 625(1-3):181-9. PubMed ID: 19825371
[TBL] [Abstract][Full Text] [Related]
16. Onconase cytotoxicity relies on the distribution of its positive charge.
Turcotte RF; Lavis LD; Raines RT
FEBS J; 2009 Jul; 276(14):3846-57. PubMed ID: 19523116
[TBL] [Abstract][Full Text] [Related]
17. [Effective expression of ribonuclease-onconase in Escherichia coli and assaying its cytotoxic potential].
Xu GF; Wang QC; Gong XG; Fei J
Shi Yan Sheng Wu Xue Bao; 2004 Jun; 37(3):227-31. PubMed ID: 15323425
[TBL] [Abstract][Full Text] [Related]
18. Contribution of structural peculiarities of onconase to its high stability and folding kinetics.
Arnold U; Schulenburg C; Schmidt D; Ulbrich-Hofmann R
Biochemistry; 2006 Mar; 45(11):3580-7. PubMed ID: 16533040
[TBL] [Abstract][Full Text] [Related]
19. The crystal structure of the domain-swapped dimer of onconase highlights some catalytic and antitumor activity features of the enzyme.
Gotte G; Campagnari R; Loreto D; Bettin I; Calzetti F; Menegazzi M; Merlino A
Int J Biol Macromol; 2021 Nov; 191():560-571. PubMed ID: 34563576
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of tumor necrosis factor induced apoptosis by onconase.
Deptala A; Halicka HD; Ardelt B; Ardelt W; Mikulski SM; Shogen K; Darzynkiewicz Z
Int J Oncol; 1998 Jul; 13(1):11-6. PubMed ID: 9625797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
